Biotech : Abbie


ABBIE is a revolutionary technology that can edit the DNA of living cells with unprecedented precision and efficiency. It has the potential to transform the field of cardiology by enabling new ways of discovering and developing drugs, as well as treating heart disease. In this post, we will explore two of the main applications of ABBIE in cardiology: drug discovery and gene therapy.

Drug discovery is the process of finding new compounds that can modulate the function of a biological target, such as a protein, RNA, or a gene that is involved in a disease. ABBIE can facilitate drug discovery by allowing researchers to edit the DNA of cells in a dish (in vitro) and make them express a specific gene that is related to a cardiac disease. For example, ABBIE can be used to create cells that have a mutation in a gene that causes cardiomyopathy, a condition that adversely affects the heart muscle. These cells can then be exposed to different drugs and screened for their effect on the mutated cells and function thereof. In this manner, ABBIE can help identify new pharmacological candidates that can potentially treat or prevent a condition such as cardiomyopathy.

Gene therapy is the delivery of genetic material into cells to correct or modify their function. ABBIE can enable gene therapy by allowing researchers to edit the DNA of cells directly in the body (in vivo) and alter their behavior or activity. For example, ABBIE can be used to target and modify the cardiac conduction cells of the heart, which are responsible for generating and transmitting electrical signals that coordinate the heartbeat. ABBIE can be used to correct or enhance the function of these cells in patients who have genetic conditions that affect their cardiac conduction system, such as long QT syndrome or Brugada syndrome. By doing so, ABBIE can help restore normal heart rhythm and prevent arrhythmias or sudden cardiac death in these patients.

Our Commitment:

Our team of experts has years of experience in the field of gene editing and related technologies. We use the latest techniques and equipment to ensure the highest level of precision in all our work. We are committed to staying at the forefront of gene editing and related technologies. That’s why we invest heavily in research and development, and work closely with leading experts in the field

At Sohm, we understand that every project is unique. That’s why we work closely with our clients to develop custom solutions that meet their specific needs and goals

UACI Partnership

We are proud to partner with the prestigious industry experts UACI. They offer leaders of science and technology startups the expertise, connections to the University of Arizona, incubation programs and office and lab space needed to turn ideas and inventions into strong, scalable and sustainable businesses that ultimately provide high-paying jobs and fuel Southern Arizona’s economy. As Arizona’s leading incubation organization, with nearly two decades of successful outcomes, UACI is a critical component of Arizona’s innovation ecosystem. This is done through providing access to people, programming and places that help entrepreneurs take their companies from idea to market


Our Capabilities:

We offer a range of products and services focused on gene editing and related technologies. Our main product, ABBIE, is a binding-based integrating enzyme that combines the targetability of the Cas9 system with viral integrases as a fusion molecule, intended for use in targeted integration experiments. We also offer consulting services, custom solutions, and innovative technologies to help our clients achieve their goals in this exciting and rapidly evolving field.




Our Publications:

Information coming soon and will be published below.


Let’s Work Together! Book your visit.